MX2018001041A - Concentrado que contiene alprostadil. - Google Patents
Concentrado que contiene alprostadil.Info
- Publication number
- MX2018001041A MX2018001041A MX2018001041A MX2018001041A MX2018001041A MX 2018001041 A MX2018001041 A MX 2018001041A MX 2018001041 A MX2018001041 A MX 2018001041A MX 2018001041 A MX2018001041 A MX 2018001041A MX 2018001041 A MX2018001041 A MX 2018001041A
- Authority
- MX
- Mexico
- Prior art keywords
- concentrate containing
- alprostadil
- pharmaceutically acceptable
- organic solvent
- acceptable organic
- Prior art date
Links
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 title abstract 3
- 229960000711 alprostadil Drugs 0.000 title abstract 3
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 title abstract 3
- 239000012141 concentrate Substances 0.000 title abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 239000003978 infusion fluid Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 239000011877 solvent mixture Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a una composición farmacéutica líquida en forma de un concentrado para la preparación de una solución para infusión, que contiene, especialmente que está constituida por, alprostadil (prostaglandina E1) como principio activo, disuelto en un disolvente orgánico farmacéuticamente aceptable o en una mezcla de disolventes de al menos un disolvente orgánico farmacéuticamente aceptable y agua, para uso en el tratamiento de enfermedad arterial oclusiva periférica (EAOP) mediante infusión intrarterial (i.a.).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ATA50664/2015A AT517555A1 (de) | 2015-07-27 | 2015-07-27 | Konzentrat enthaltend Alprostadil |
| PCT/AT2016/060019 WO2017015691A1 (de) | 2015-07-27 | 2016-07-25 | Konzentrat enthaltend alprostadil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018001041A true MX2018001041A (es) | 2018-06-07 |
Family
ID=56852016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001041A MX2018001041A (es) | 2015-07-27 | 2016-07-25 | Concentrado que contiene alprostadil. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3328357B1 (es) |
| AR (1) | AR105503A1 (es) |
| AT (1) | AT517555A1 (es) |
| BR (1) | BR112018000525A2 (es) |
| CO (1) | CO2018000526A2 (es) |
| MX (1) | MX2018001041A (es) |
| PE (1) | PE20180606A1 (es) |
| WO (1) | WO2017015691A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05864B1 (et) * | 2021-12-22 | 2024-02-15 | Aktsiaselts Kevelt | 3-hüdroksütsüklopentoonitsüklit sisaldava ühendi kompositsioon ja meetod selle stabiliseerimiseks |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4309579C3 (de) * | 1993-03-24 | 2000-01-27 | Sanol Arznei Schwarz Gmbh | Pharmazeutische Zusammensetzung in Form einer Packung |
-
2015
- 2015-07-27 AT ATA50664/2015A patent/AT517555A1/de not_active Application Discontinuation
-
2016
- 2016-07-25 PE PE2018000130A patent/PE20180606A1/es unknown
- 2016-07-25 BR BR112018000525-8A patent/BR112018000525A2/pt not_active IP Right Cessation
- 2016-07-25 EP EP16759665.9A patent/EP3328357B1/de active Active
- 2016-07-25 MX MX2018001041A patent/MX2018001041A/es unknown
- 2016-07-25 WO PCT/AT2016/060019 patent/WO2017015691A1/de not_active Ceased
- 2016-07-27 AR ARP160102284A patent/AR105503A1/es unknown
-
2018
- 2018-01-19 CO CONC2018/0000526A patent/CO2018000526A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018000525A2 (pt) | 2018-09-18 |
| PE20180606A1 (es) | 2018-04-09 |
| AT517555A1 (de) | 2017-02-15 |
| WO2017015691A1 (de) | 2017-02-02 |
| EP3328357A1 (de) | 2018-06-06 |
| AR105503A1 (es) | 2017-10-11 |
| EP3328357B1 (de) | 2020-12-09 |
| CO2018000526A2 (es) | 2018-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016134223A3 (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
| EA201791019A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| EA028928B9 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
| PH12015502539B1 (en) | Cenicriviroc compositions and methods of making and using the same | |
| EA201692280A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| EA201590058A1 (ru) | Аналоги глюкагона | |
| PH12018500576A1 (en) | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | |
| EP4360621A3 (en) | Formulations of bendamustine | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| NZ733313A (en) | Indole derivatives as dengue viral replication inhibitors | |
| TW201613909A (en) | Benzoxazinone amides as mineralocorticoid receptor modulators | |
| WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
| EA201691741A1 (ru) | Фармацевтическая композиция | |
| EA201890788A1 (ru) | Препараты оланзапина с замедленным высвобождением | |
| MX384987B (es) | Derivados del ácido acético azaindol y su uso como moduladores de receptor de prostaglandina d2. | |
| MX2018001041A (es) | Concentrado que contiene alprostadil. | |
| MD20180049A2 (ro) | Compoziţie farmaceutică | |
| MX369244B (es) | Solucion alcoholica estable de alprostadilo. | |
| MX377481B (es) | Derivados de serina como agonistas del receptor de grelina. | |
| EA201790750A1 (ru) | Назальная лекарственная композиция, содержащая морскую воду в качестве вспомогательного вещества, улучшающего стабильность препарата | |
| MX2016013979A (es) | Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina. | |
| MX2018001042A (es) | Concentrado que contiene alprostadil. | |
| EA201892095A1 (ru) | Циклические динуклеотидные соединения и способы их применения | |
| IN2014MU01178A (es) | ||
| EA201690240A1 (ru) | Новые соединения индазола и способ их получения |